Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.
The news feed for Sonnet BioTherapeutics Holdings, Inc. (formerly Nasdaq: SONN) provides an archive of company announcements, clinical updates, financing disclosures, and corporate transaction news. Sonnet is described as an oncology-focused biotechnology company that develops targeted biologic drugs using its proprietary FHAB (Fully Human Albumin Binding) platform, and its news releases highlight both scientific progress and significant strategic developments.
Readers can review detailed updates on Sonnet’s lead program, SON-1010 (IL‑12‑FHAB), including Phase 1b/2a trial data from the SB221 study in advanced solid tumors and platinum-resistant ovarian cancer. Company news has discussed dose-escalation results, safety and tolerability findings, partial responses observed at higher dose levels, and plans for expansion cohorts and randomized proof-of-concept stages. Additional releases cover SON-1210, an IL12-FHAB-IL15 construct for solid tumors, and collaborations such as those with Roche and the Sarcoma Oncology Center.
The news archive also documents Sonnet’s participation in industry conferences, virtual investor events, and educational segments where members of management and clinical leadership discuss trial design, safety data, and the scientific rationale behind the FHAB platform. These communications offer context on how Sonnet approaches issues like cytokine toxicity, therapeutic windows, and tumor microenvironment targeting.
A major theme in recent news is the business combination between Sonnet BioTherapeutics Holdings, Inc., Hyperliquid Strategies Inc., and Rorschach I LLC. Press releases outline the terms of the transaction, the creation of Hyperliquid Strategies Inc. as a digital asset treasury company focused on the HYPE token, and the resulting structure in which Sonnet becomes a wholly owned subsidiary. These items explain that Hyperliquid Strategies Inc.’s common stock is expected to trade on Nasdaq under the ticker PURR and that Sonnet’s common stock will no longer trade separately.
By following this news stream, investors and observers can see how Sonnet’s clinical developments, financing activities, governance decisions, and corporate transformation have been communicated over time. The archive helps place individual announcements in the broader context of the company’s oncology pipeline and its integration into a parent entity focused on digital asset treasury management.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) reported progress in its Phase 1 clinical trials for SON-1010, an immunotherapeutic drug. The company is enrolling the final dose cohort for the cancer trial (SB101) which has dosed 15 patients, with 36% showing clinical benefit based on stable disease results. No dose-limiting toxicities were observed, and adverse events were mostly mild and transient. SON-1010 demonstrated a prolonged half-life, with pharmacokinetic data suggesting effective targeting of tumors. The next steps include investigating SON-1010's impact on platinum-resistant ovarian cancer. Sonnet's current financial position allows for operational activities into 2024. A webinar discussing these results is scheduled for today at 5 pm ET.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN), a clinical-stage biopharmaceutical firm, announced a webcast on April 18, 2023, at 5:00 pm ET to present data from its SB101 study with SON-1010 involving oncology patients (NCT05352750). Presenters include Richard Kenney, M.D. and Pankaj Mohan, Ph.D.. The webcast will offer a detailed overview of the clinical trial and will be available for later access on the company's website. Also, a poster presentation titled Clinical development of a novel form of interleukin-12 will occur during the AACR 2023 Annual Meeting on April 18, from 1:30 pm to 5:00 pm ET. Sonnet's FHB technology aims to enhance the efficacy of immunotherapeutic drugs by targeting tumor tissues effectively, which is essential for its ongoing clinical applications.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced it will present data from the SB101 multiple-dose clinical trial of SON-1010 (IL12-FHAB) at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. The presentation, titled "Clinical development of a novel form of interleukin-12 with extended pharmacokinetics," is scheduled for April 18, 2023, from 1:30 PM to 5:00 PM. SON-1010 is designed for treating adult patients with advanced solid tumors and utilizes FHAB technology for improved targeting of tumor and lymphatic tissues. This marks a significant step in Sonnet's commitment to advancing oncology treatments.
FAQ
What is the current stock price of Sonnet Biotherapeutc Hldng (SONN)?
What is the market cap of Sonnet Biotherapeutc Hldng (SONN)?
